Panacea Biotec has entered into a joint collaboration with US generic drug maker Bionpharma Inc to develop, manufacture and sell seven complex generic drugs. The company is likely to focus on the immuno-suppressant therapy area which are estimated to have a market potential of $800 million. As per the agreement, Panacea will be responsible for development, filing, registration, manufacture and supply of these generic drugs (Abbreviated New Drug Applications), while Bionpharma will be responsible for importing, warehousing, sales and distribution of these ANDAs in the United States and its territories.
Leave a Reply